Bühler, A
Wendtner, C-M
Kipps, T J
Rassenti, L
Fraser, G A M
Michallet, A-S
Hillmen, P
Dürig, J
Gregory, S A
Kalaycio, M
Aurran-Schleinitz, T
Trentin, L
Gribben, J G
Chanan-Khan, A
Purse, B
Zhang, J
De Bedout, S
Mei, J
Hallek, M
Stilgenbauer, S
Article History
Received: 17 January 2016
Accepted: 2 February 2016
First Online: 11 March 2016
Competing interests
: C-MW receives research funding, consultancy and honoraria by Celgene; MH receives research support from Celgene; TJK has served as an advisor to Celgene and received research funding from Celgene; GAMF has received honoraria from Celgene; PH receives honoraria from Celgene; JD has received a research grant and honoraria from Celgene; JGG receives honoraria from Celgene, Roche, Pharmacyclics, Mundipharma and Abbvie, and has received research support grant funding from Celgene; BP is an employee of Celgene and has equity; JZ is an employee of Celgene and has equity; SDB is an employee of Celgene and has equity; JM is an employee of Celgene and has equity; SS has received a research grant and honoraria from Celgene; the remaining authors declare no conflict of interest.